Indoleamine-2,3-dioxygenase (IDO) is an intracellular enzyme which catalyzes the initial and rate limiting step in the degradation pathway of the essential amino acid tryptophan and is expressed in professional APCs, epithelial cells, vascular endothelium and tumor cellsIDO is a crucial enzyme in the initiation and spread of cancer. It encourages tumor angiogenesis, immune tolerance to tumor antigens in stromal and immune cells, suppression of T and NK cells, production and activation of T regulatory cells (Tregs), and myeloid-derived suppressor cells. It also supports inflammation in the tumor microenvironment.According to reports, functionally active IDO protein is expressed in a wide range of human hematologic malignancies, including breast cancer, colorectal cancer, endometrial cancer, gastric cancer, glioblastoma, gynecological cancers, head and neck cancers, non-small cell lung cancer (NSCLC), melanoma, and pancreatic cancer. The IDO pathway is emerging as a crucial method for the treatment of cancer as an immune checkpoint pathway.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V73184 | (R)-IDO/TDO-IN-1 | 2033173-00-9 | (R)-IDO/TDO-IN-1 (compound 25) is an indoleamine-2,3-dioxygenase (IDO) inhibitor (antagonist) with good pharmacokinetic properties. |
|
V51717 | 1-Isopropyltryptophan (1-IsoPT) | 1219485-46-7 | 1-Isopropyltryptophan (1-IsoPT) is an IDO1 inhibitor. |
|
V51729 | 4-Phenyl-1H-1,2,3-triazole | 1680-44-0 | 4-Phenyl-1H-1,2,3-triazole is an IDO1 inhibitor (IC50= 60 μM). |
|
V87527 | AT-0174 | AT-0174 is an orally active dual inhibitor of IDO1/TDO2 (tryptophan 2,3-dioxygenase-2) with IC50 values of 0.17 and 0.25 μM, respectively. | |
|
V51724 | BMS-986242 | 1923844-48-7 | BMS-986242 is an orally bioactive, potent and specific inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1). |
|
V51718 | BMT-297376 | 2251031-81-7 | BMT-297376 is an optimized Linrodostat and a potent IDO1 inhibitor. |
|
V51720 | CAY-10581 | 1018340-07-2 | CAY10581, a pyranophanequinone analogue, is a specific and reversible noncompetitive IDO inhibitor (antagonist) with IC50 of 55 nM. |
|
V51723 | DP-00477 | 169120-56-3 | DP00477 is a potent IDO1 (indoleamine 2,3-dioxygenase 1) couple with IC50 of 7.0 µM. |
|
V73187 | IDO antagonist-1 | 2206797-88-6 | IDO antagonist-1 (compound 163) is an antagonist of IDO. |
|
V37567 | IDO-IN-13 (GS4361) | 2291164-02-6 | IDO-IN-13 (GS-4361), extracted from patent WO2019040102A1, example 43, is a novel and potent indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor with EC50 of 17 nM. |
|
V51711 | IDO-IN-14 | 2568302-02-1 | IDO-IN-14 is an IDO inhibitor (antagonist) with IC50 of 0.6928 nM. |
|
V51710 | IDO-IN-15 | 2433886-87-2 | IDO-IN-15 is an IDO1 inhibitor (IC50 < 0.51 nM). |
|
V51708 | IDO-IN-18 | 314027-92-4 | IDO-IN-18 (Compound 00815) is an IDO inhibitor. |
|
V51707 | IDO1-IN-11 | 2306411-34-5 | IDO1-IN-11 is an IDO1 inhibitor (antagonist) with IC50 of 0.6 nM. |
|
V51706 | IDO1-IN-12 | 2379570-48-4 | IDO1-IN-12 is a potent and orally bioavailable IDO1 inhibitor. |
|
V51705 | IDO1-IN-21 | 2892432-98-1 | IDO1-IN-21 (Compound 10m) is an IDO1 inhibitor (IC50 = 0.64 μM). |
|
V73185 | IDO1-IN-22 | 2126853-16-3 | IDO1-IN-22 (Compound 3) is an IDO1 inhibitor (biochemical hIDO1 IC50= 67.4 nM, hIDO1 IC50 in HeLa cells: 17.6 nM). |
|
V79863 | IDO1-IN-23 | 3007671-44-2 | IDO1-IN-23 (compound 41) is a potent inhibitor of human IDO1 with IC50 of 13 μM. |
|
V87525 | IDO1-IN-24 | IDO1-IN-24 (compound 2c) inhibits the production of IDO1 in cell-based assays with an IC50 value of 17 μM. | |
|
V97638 | IDO1-IN-25 | 2841467-86-3 | IDO1-IN-25 is a dual IDO1/TDO2 inhibitor with IC50 values of 0.17 μM and 3.2 μM, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
